Preempting Coronary Ischemia – Expanding the Spectrum of Cardiac Biomarkers

MPO testing provides prognostic information in addition to troponin and hsCRP testing, revealing a more complete clinical picture of the CVD patient. It may also add incremental value when used with other biomarkers, particularly in troponin-negative patients, enabling treatment before more severe myocardial damage occurs.

Learn more about MPO

Reliable Answers to Critical Cardiac Questions

As a recognized worldwide leader in CVD testing, Siemens Healthcare Diagnostics offers MPO testing across multiple instrument solutions to help provide a more complete clinical picture of the CVD patient.

Features:

• Fully automated, no-pretreatment MPO
• Can be run on same instrument along with other cardiac markers
• Same turnaround time as troponin